The standard of care for hypertrophic cardiomyopathy has undergone a lot of change in recent years. Many more changes are likely on the way.

The newly cleared pVasc NET includes a dual-layer filter not available on the company's previous devices. 

Bill Shields, who spent a 15 years with Medtronic’s structural heart division, will now be helping lead a startup focused on tricuspid valve treatments. 

The SPARC trial will enroll up to 125 patients with peripheral artery disease. 

Veteran cardiologist Jonathan Reiner, MD, a professor at George Washington University, shared his concerns about President Donald Trump's health. 

TAVR can be especially challenging in patients with PAR and an enlarged LVOT. Specialists in China have developed a new technique that could improve outcomes for some of these patients without introducing new risks. 

Researchers at Duke are hard at work on digital twins that could help care teams make important treatment decisions. 

Novartis recalled a single lot of valsartan, a blood pressure/heart failure drug the company sells under the brand name Diovan. According to the FDA, this is a Class II recall.

The greatest opportunity is detecting coronary atherosclerosis in younger patients undergoing CT for unrelated reasons, including trauma evaluations.

FAI CCTA imaging uses AI to show coronary inflammation and a patient's specific residual risk of heart attack that is not available using current testing methods.

Matthew Budoff, MD, explains how AI-powered plaque analysis and FFR-CT are transforming cardiac preventive care.
 

Rather than moving quickly to adopt new tools, the Tucson, Arizona-based doc-certification organization is studying developments, engaging experts and establishing guardrails before introducing any change.  

The lawsuit touches on the common complaint of third-party tracking code being used on websites that in some cases captures sensitive information in patient portals and search forms. UCHealth denies the allegations.